MOBA

MOBA is a clinical-stage biotechnology company leveraging its proprietary MOBA-seq platform to systematically map and target the genetic drivers of cancer metastasis. The platform integrates scalable barcode-based lineage tracing with high-throughput CRISPR screening to quantify genotype-specific effects on metastatic seeding, dormancy, and expansion at single-colony resolution. By generating hundreds of thousands of high-resolution in vivo data points, MOBA identifies novel therapeutic targets for aggressive malignancies like small cell lung cancer (SCLC). The company's mission is to disrupt the metastatic cascade and provide new treatment options for patients with extensive-stage metastatic disease. MOBA's approach uniquely combines tumor-intrinsic insights with an understanding of immune-modulatory mechanisms in the metastatic microenvironment.